Another approach to target tumor heterogeneity involves conjugating a single antibody with two distinct cytotoxic medicines, which demonstrated superior tumor killing and survival benefits compared to combinations of single-drug ADCs in models of HER2 heterogeneity and resistance [58]. The gene discussed is ERBB2; the disease is neoplasm.